NCT00079989View on ClinicalTrials.gov

Study Evaluating Tigecycline in Selected Serious Infections Due to Resistant Gram-Negative Organisms

PHASE3CompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions
Gram-Negative Bacterial Infections
Interventions
DRUG

tigecycline

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00079989 - Study Evaluating Tigecycline in Selected Serious Infections Due to Resistant Gram-Negative Organisms | Biotech Hunter | Biotech Hunter